AbbVie Inc (ABBV)vsCryoCell International Inc (CCEL)
ABBV
AbbVie Inc
$286.20
+0.94%
HEALTHCARE · Cap: $520.47B
CCEL
CryoCell International Inc
$4.15
0.00%
HEALTHCARE · Cap: $39.10M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 211982% more annual revenue ($66.01B vs $31.13M). ABBV leads profitability with a 15.7% profit margin vs -6.3%. ABBV appears more attractively valued with a PEG of 0.59. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
CCEL
Hold47
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-79.8%
Fair Value
$157.70
Current Price
$286.20
$128.50 premium
Margin of Safety
+33.5%
Fair Value
$5.02
Current Price
$4.15
$0.87 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 36.6%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Every $100 of equity generates 129 in profit
Earnings expanding 75.1% YoY
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% revenue growth
Smaller company, higher risk/reward
Operating margin of 0.6%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 36.6%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : CCEL
The strongest argument for CCEL centers on Return on Equity, EPS Growth, Debt/Equity. PEG of 1.34 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.6x leaves little room for execution misses.
Bear Case : CCEL
The primary concerns for CCEL are Revenue Growth, Market Cap, Operating Margin.
Key Dynamics to Monitor
ABBV profiles as a mature stock while CCEL is a turnaround play — different risk/reward profiles.
CCEL carries more volatility with a beta of 0.55 — expect wider price swings.
ABBV is growing revenue faster at 10.3% — sustainability is the question.
ABBV generates stronger free cash flow (7.3B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 47/100), backed by strong 15.7% margins and 10.3% revenue growth. CCEL offers better value entry with a 33.5% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
CryoCell International Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Cryo-Cell International, Inc. is dedicated to cell processing and cryogenic cell storage with a focus on collecting and preserving umbilical cord blood stem cells for family use. The company is headquartered in Oldsmar, Florida.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?